Curis Reports Second Quarter 2017 Financial Results
Aug 03, 2017 11:00 am UTC| Business
LEXINGTON, Mass., Aug. 03, 2017 -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers,...
MediWound Reports Second Quarter 2017 Financial Results
Aug 03, 2017 11:00 am UTC| Business
NexoBrid® sales double in first half of 2017 BARDA upsizes committed funding by additional $32 million, bringing total contract value to up to $132 million of non-dilutive financing Conference call begins today at 8:30...
Brown & Brown, Inc. Announces the Asset Acquisition of Clairmont Financial Group
Aug 03, 2017 11:00 am UTC| Business
DAYTONA BEACH, Fla., Aug. 03, 2017 -- J. Scott Penny, Chief Acquisitions Officer of Brown Brown, Inc. (NYSE:BRO), and James Clairmont, the founder of Clairmont Financial Group, LLC ("Clairmont Financial"), today...
Aug 03, 2017 11:00 am UTC| Business
HOUSTON, Aug. 03, 2017 -- American Electric Technologies, Inc. (NASDAQ:AETI) (the “Company”), a leading supplier of power delivery solutions for the global energy industry, today reported that it has entered into a...
EMCORE Corporation Announces Financial Results for Third Quarter Ended June 30, 2017
Aug 03, 2017 11:00 am UTC| Business
Consolidated Q3 revenue of $31 million Consolidated Q3 GAAP operating income of $2.0 million and Non-GAAP operating income of $3.6 million GAAP EPS from continuing operations of $0.09 and Non-GAAP pre-tax EPS from...
Aug 03, 2017 11:00 am UTC| Business
Filing includes results of head-to-head Phase 3 clinical trial evaluating Feraheme compared to ferric carboxymaltose injection Potential approval and launch in the first half of 2018 WALTHAM, Mass., Aug. 03, 2017 --...
Summit Therapeutics to Present at the Canaccord Genuity Growth Conference
Aug 03, 2017 11:00 am UTC| Business
OXFORD, UNITED KINGDOM, Aug. 03, 2017 -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and Clostridium difficile...